| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |